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Abstract
Epigenetic processes - including DNA methylation - are increasingly seen as having a fundamental role in chronic diseases
like cancer. It is well known that methylation levels at particular genes or loci differ between normal and diseased tissue.
Here we investigate whether the intra-gene methylation architecture is corrupted in cancer and whether the variability of
levels of methylation of individual CpGs within a defined gene is able to discriminate cancerous from normal tissue, and is
associated with heterogeneous tumour phenotype, as defined by gene expression. We analysed 270985 CpGs annotated to
18272 genes, in 3284 cancerous and 681 normal samples, corresponding to 14 different cancer types. In doing so, we found
novel differences in intra-gene methylation pattern across phenotypes, particularly in those genes which are crucial for stem
cell biology; our measures of intra-gene methylation architecture are a better determinant of phenotype than measures
based on mean methylation level alone (K-S test pv10{3 in all 14 diseases tested). These per-gene methylation measures
also represent a considerable reduction in complexity, compared to conventional per-CpG beta-values. Our findings
strongly support the view that intra-gene methylation architecture has great clinical potential for the development of DNA-
based cancer biomarkers.
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Introduction
Epigenetic information is stored in the genome in the form of
heritable modifications to the chemical structure of DNA, such as
methylation of particular bases, as well a variety of chemical
modifications of the histone proteins which package the DNA.
Epigenetic information can be modulated during the lifetime of an
organism by environmental cues [1–3] and these changes persist in
subsequent mitoses, leading to an acquired change of phenotype.
DNA methylation is an epigenetic mark consisting almost
entirely of the methylation of CpG dinucleotides [4], and it is
possible for one, both, or neither alleles at a particular genomic
locus to be methylated [5]. Hypermethylation of CpGs in the gene
promoter (the region close to the transcriptional start site, TSS) are
incontrovertibly associated with silencing of the corresponding
gene, and this effect is particularly important in cancer, where
aberrant gene silencing is associated with functional changes
important in every stage of tumour progression [6].
It has been found previously that variability of methylation at
specific genomic locations is important in the development of
cancer [7]. It has been noted in particular that there is an increase
in stochastic methylation variability in regions which are already
known to have altered levels of methylation in cancers, leading to
aberrant and varying gene expression, and providing an epigenetic
mechanism for tumour heterogeneity [8]. It has also been shown
recently that statistics based on differential variability of methyl-
ation can lead to improved detection of risk markers in pre-
cancerous growths [9,10].
Polycomb group proteins (PcG) play a fundamental role in
developmental processes, maintaining a class of genes known as
polycomb group targets (PCGTs) in a repressed state in ES
(embryonic stem) cells, to maintain pluripotency, and ‘poised for
activation’ during differentiation [11]. The link between PCGTs
and cancer has been discussed by many authors [12–14]; it was
recently shown that DNA hypermethylation in cancers preferen-
tially targets PCGTs which are developmental regulators [15],
those authors hypothesising that this may contribute to the stem-
like characteristics of cancer; in further support of these ideas it has
been noted that tumours which are particularly poorly differen-
tiated tend to display expression patterns which are similar to ES
cells, including repression of PCGTs [16].
Polycomb group proteins maintain the repressed state of genes
via chromatin (the DNA packaging); DNA in its compact state is
wrapped around histone proteins (a main component of chroma-
tin), and PRC2 (polycomb repressive complex 2) is responsible for
the trimethylation of lysine 27 of histone 3 (leading to the
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epigenetic mark H3K27me3), which is associated with this
compact state [17]. Genes occupied by PRC2 in ES cells mostly
carry bivalent chromatin marks [15]; bivalency includes the
histone modification H3K4me3 (trimethylation of lysine 4 on
histone 3), a mark which is associated with activation of the
corresponding gene, in addition to the repressive H3K27me3
mark. It is thought that it is this bivalent state which maintains
stemness, keeping the gene repressed, but poised for activation
upon differentiation. As DNA methylation is also associated with
repression and activation of genes, it is of interest whether the
methylation patterns of genes which carry the chromatin markings
H3K27me3 and/or H3K4me3 in stem cells are altered in cancer,
as such aberrant alteration of gene regulation via DNA
methylation might be associated with a return of or accentuation
of stem-like cell characteristics.
The role of early epigenetic changes in oncogenic transforma-
tion, including disruption of the healthy epigenotype of progenitor
cells, the creation of an epigenetically permissible environment in
which genetic aberrations can have tumorigenic effects, and
phenotypic plasticity leading to tumour adaptation and associated
with intra-tumour heterogeneity, was originally proposed by
Feinberg and colleagues [1]. It is hypothesised that one way in
Figure 1. Per-gene methylation measures. (a) The mean z-score measure is calculated for tumour sample j (shown in red) for gene g (to which n
probes map), from the mean, mi , and standard deviation, si , of the healthy control samples at each probe i (b) The methylation profiles of 586 cancer
(red) and 98 healthy (blue) samples across a gene found as significant according to the mean z-score measure, with probes spaced (unevenly)
according to their genomic loci. Genomic regions are indicated under the gene with the colour code displayed at the bottom of the figure. (c) A
heatmap illustrating the same gene, with probes evenly spaced; b values for each sample and each probe are indicated by the colour code displayed
at the top of the figure. Samples are plotted in order of mean z-score, such that the tumour sample with the smallest mean z-score and the healthy
sample with the smallest mean z-score are adjacent. Genomic regions are indicated under the gene with the colour code displayed at the bottom of
the figure. N.B., this gene has two transcriptional start sites (TSSs) in different locations. (d) The mean derivative measure is calculated, for sample j, as
the mean of the absolute differences in the corresponding b values between consecutive probes, across the whole of gene g. (e) The mean
methylation measure is calculated, for sample j, as the mean of the corresponding b values of the probes annotated to a particular genomic region of
g. (f) The methylation variance measure is calculated, for sample j, as the variance of the corresponding b values of the n’ probes annotated to a
particular genomic region of g. N.B., (d)-(f) are calculated without reference to healthy samples, whereas (a) is calculated with reference to healthy
samples.
doi:10.1371/journal.pone.0068285.g001
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which stochastic dysregulation of stem cell genes and associated
phenotypic heterogeneity might manifest, is in terms of cell to cell
variability of methylation; this would in turn be expected to
correlate with intra-gene variability of methylation, as measured
using aggregated mixtures of heterogenous cells in a microarray
experiment.
Intra-gene methylation variability is deemed to be a disruption
of the normal methylation profile, or architecture, of a particular
gene, and such a change may be more generally linked to the
creation of an epigenetically permissible environment for onco-
genic transformation, and to tumourigenesis. Such changes would
be expected to accompany the early stages or even precede the
onset of the disease, and hence identifying reliable indicators of
such changes might provide a valuable lead for the development of
DNA-based cancer biomarkers in bodily fluids, especially as it has
been shown recently that DNA methylation biomarkers related to
stem cell genes are associated with clinical outcome in women’s
cancers [18].
Previous studies [7,9,10] have focussed on the effects of sample
to sample variability of methylation; here for the first time, we
analyse the association of phenotype with intra-gene variability of
methylation. Making use of data derived from the Illumina
Infinium HumanMethylation450 platform, which interrogates
w485000 CpGs genome-wide including w330000 with known
gene annotations (corresponding to on average 17 CpGs per gene),
we have investigated measures of intra-gene methylation archi-
tecture, and their ability to differentiate between healthy and
disease phenotypes. For this we have developed new measures,
and adapted standard ones.
Results
To investigate intra-gene methylation architecture, four gene-
centric measures are considered, as follows:
1. The mean deviation of the sample methylation profile from the
mean methylation profile of healthy phenotype control
samples, for each gene. This mean methylation profile may
fluctuate a lot within each gene, and so it is not the same as the
mean methylation level of a gene. Because this mean deviation
is normalised at every probe by dividing by the probe standard
deviation across the healthy phenotype control samples, it is
called the ‘mean z-score’ measure; this is illustrated in
Figure 1(a). An example of one of the genes found to be most
significant according to this measure is shown in Figure 1(b)
and (c).
2. The mean derivative of the methylation measurements for each
gene. The derivative of the methylation profile for a given gene
and sample is approximated by the differences between the
methylation values measured at consecutive probes mapping to
that gene. The mean of the absolute values of these differences
is then calculated as the ‘mean derivative’ measure; this is the
same as the sum total of all the increases and decreases in
methylation level from one probe to the next across the gene;
this is illustrated in Figure 1(d). This is a self-calibrating
measure of intra-gene methylation variability, because it is
calculated for a given sample from the differences within that
sample, and without reference to any other sample.
3. The mean of the methylation measurements for a particular
genomic region for each gene; this is illustrated in Figure 1(e).
Typical mean methylation levels vary greatly from one
genomic region to another; hence the mean methylation level
for a particular genomic region was used as the ‘mean
methylation measure’ for a gene, and the same region was
used for each gene.
4. The variance for each gene of the methylation measurements
for a particular genomic region; this is illustrated in Figure 1(f).
Because variance is calculated in relation to the mean, this
measure was similarly calculated for each gene using only the
probes mapping to a particular genomic region, again using the
same genomic region for each gene. This is called the
‘methylation variance’ measure; it is another self-calibrating
measure.
These four measures each seek to examine a different
characteristic of intra-gene methylation architecture, and all are
able to classify samples one-by-one, i.e., they are intra-gene or
intra-sample measures, rather than sample to sample measures as
has been investigated previously in the context of methylation
variability.
As the mean z-score is calculated as a mean measure of
methylation difference from the healthy methylation profile,
strictly speaking it is a measure of methylation instability. The
mean derivative and methylation variance measures are both
measures of intra-gene methylation variability; however, the mean
derivative is calculated with reference to the ordering of the probes
(i.e., this measure would return a different number if the order of
the probes was randomised) whereas the methylation variance
would not; the mean derivative additionally considers all probes
mapping to the gene, whereas the methylation variance measure
only considers probes mapping to a particular genomic region.
The mean methylation measure is unique here in that it does not
measure difference in methylation level and instead measures
absolute methylation level; it is included here mainly for
comparison.
The properties of these four measures were initially investigated
in the context of fourteen Illumina Infinium Human Methylation
450 data sets, which were downloaded from The Cancer Genome
Atlas (TCGA) [19]. We applied these four measures to the
fourteen TCGA data sets; in all, we analysed 450 K DNAm data
from 3284 tumour and 681 healthy samples; details of the number
of samples of each phenotype and in each data set are shown in
Table 1 (for data set abbreviations, see ‘Methods and Models’). We
also carried out a meta-analysis of these data which is to our
knowledge the largest meta-analysis performed in any DNA
methylation study.
Comparison of Intra-gene Methylation Measures
As a preliminary assessment of the relative merits of these four
measures, we looked at their ability to distinguish between tumour
and healthy tissue. The correlation of the tissue sample phenotype
to the four methylation measures was considered in terms of
distributions of per-gene AUCs (area under curve, which is a
measure of prediction accuracy, see ‘Methods and Models’ for
details). These distributions are shown in box-plots in Figure 2. For
every data set, the mean z-score measure is significantly better at
discriminating tumour from healthy tissue using these methylation
data, than the mean derivative measure, the methylation variance
measure, and the mean methylation measure (visual comparison of
Figure 2 was confirmed by Kolmogorov-Smirnov tests, data not
shown); this is because the mean z-score measure is defined
relative to the healthy mean methylation profile. Excluding the
mean z-score measure, the mean methylation measure is
significantly better at discriminating tumour from healthy tissue
than the remaining two measures in ten of the remaining data sets,
with the mean derivative discriminating significantly better in two
data sets (READ and THCA), and inconclusive results for the
Intragene DNA Methylation Variability in Cancer
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remaining data sets (KIRC and PAAD, which has unstable results
due to small sample size). Figure S3 shows, in scatter plots,
pairwise comparisons of each of the four methylation measures for
a gene which was among the top 1000 genes with the highest AUC
according to each of these measures.
To directly compare the effectiveness of the mean z-score
measure at predicting phenotype (cancer/healthy) independent of
mean methylation level, a logistic regression model was fitted to
each gene using mean z-score and mean methylation as covariates,
leading to p-values for each gene for each of mean z-score and
mean methylation. In every data set except two, for the large
majority (80–100%) of those genes with at least one of the two
covariates significant, the mean z-score covariate p-value was
more significant than the corresponding mean methylation
covariate p-value. In the remaining two data sets, the mean z-
score covariate p-value was more significant for the majority (50–
80%) of genes with at least one significant covariate (detailed
results not shown). Hence, the mean z-score is a better predictor of
phenotype than the mean methylation, even after adjustment for
mean methylation level.
Meta-analysis and Gene-set Enrichment Analysis
A meta-analysis of the fourteen data sets was carried out. Genes
were assigned significance according to their mean AUC (based on
the mean z-score measure) across all data sets by a permutation
method (see ‘Methods and Models’ for details); this identified over
4000 significant genes which were associated with a consistent
difference between cancer and healthy phenotypes across tissue
types (FDR qƒ0:05). These genes consistently show the biggest
differences between healthy and cancer phenotypes (as the mean
z-score measure is defined relative to healthy control samples), and
as the mean z-score is a measure of methylation instability, they
are termed the most unstable meta-analysis genes. The mean z-
scores for individual tumour and healthy samples for the 50 most
significant of these most unstable meta-analysis genes are displayed
in Figure 3, and details about the 100 most significant of these
genes are shown in Table S1. In particular, Figure 3 shows the
extent to which the instability is consistent (high mean z-score, red)
across cancer patients as compared to healthy patients (low mean
z-score, blue). Genes with a mean AUC close to 0.5 across most
tumour types were also found; these are genes which tend to have
the smallest differences between healthy and cancer phenotypes
across tissue types and hence are marked as least unstable meta-
analysis genes. Over 2800 least unstable meta-analysis genes were
found to be significant by this permutation method (FDR qƒ0:05)
and the 100 most significant of these are shown in Table S2. There
is however less consistency among the least unstable meta-analysis
genes across tumour types, e.g., the 100th placed significant least
unstable meta-analysis gene has an AUC of less than 0.6 for only
10 out of 14 tumour types.
To confirm the biological significance of the findings of this
meta-analysis with reference to genes which are well known to be
important in cancer biology, the most unstable and least unstable
meta-analysis genes were tested for enrichment by genes which in
Table 1. Number of samples in each data set.
healthy cancer total
BRCA 98 586 684
UCEC 36 334 370
THCA 50 357 407
LUAD 32 306 338
BLCA 18 126 144
LUSC 43 227 270
COAD 38 258 296
HNSC 50 310 360
KIRC 160 283 443
LIHC 50 98 148
READ 7 96 103
PRAD 49 176 225
KIRP 44 87 131
PAAD 6 40 46
doi:10.1371/journal.pone.0068285.t001
Figure 2. Distributions of per-gene AUCs calculated from intra-gene methylation measures. Each box displays the values of the AUCs for
the 1000 most significant genes for a particular tumour type and intra-gene methylation measure. The mean z-score predicts phenotype better than
the other three measures in all 14 tumour types. Tumour type abbreviations are as follows: Bladder Urothelial Carcinoma (BLCA), Breast Invasive
Carcinoma (BRCA), Colon Adenocarcinoma (COAD), Head and Neck Squamous Cell Carcinoma (HNSC), Kidney Renal Clear Cell Carcinoma (KIRC),
Kidney Renal Papillary Cell Carcinoma (KIRP), Liver (LIHC), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Pancreatic
Adenocarcinoma (PAAD), Prostate Adenocarcinoma (PRAD), Rectum Adenocarcinoma (READ), Thyroid Carcinoma (THCA), and Uterine Corpus
Endometrioid Carcinoma (UCEC).
doi:10.1371/journal.pone.0068285.g002
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ES cells carry the repressing/activating chromatin marks
H3K27me3 (H3K27 ES genes), H3K4me3 (H3K4 ES genes)
and bivalent (i.e., both H3K27me3 and H3K4me3 marks, Biv ES
genes) and enrichment by PCGTs (ES cell polycomb group
targets). The most unstable meta-analysis genes are highly
enriched by Biv and H3K27 ES genes and PCGTs, and the least
unstable meta-analysis genes are highly enriched by H3K4 ES
genes (Table 2).
A more general gene-set enrichment analysis (GSEA) was also
carried out, testing enrichment of the most unstable and least
unstable meta-analysis genes by members of over 6000 gene sets
(see ‘Methods and Models’ section for details). The 100 most
significantly enriched of these gene sets by the most unstable and
least unstable meta-analysis genes appear in tables S3 and S4
respectively. In particular Table S3 (gene sets enriched by most
unstable meta-analysis genes) shows many developmental and cell
signalling gene sets.
Figure 3. Heatmap of the mean z-score for the top 50 genes found by the meta-analysis. Mean z-scores for tumour (T) and healthy (H)
samples are displayed in a heatmap according to the colour code for the top 50 meta-analysis genes (top 50 most consistently unstable genes). The
heatmap shows the extent to which the instability is consistent (high mean z-score, red) across cancer patients as compared to healthy patients (low
mean z-score, blue). For each tissue type healthy samples appear to the right of tumour samples; where no space is available the (H) label is omitted.
Abbreviations: R (READ), B (BLCA), K(KIRP), P (PAAD).
doi:10.1371/journal.pone.0068285.g003
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The most unstable meta-analysis genes are associated with
generally higher methylation levels than genes which are not
significant according to the meta-analysis (i.e., genes which are
neither most unstable or least unstable meta-analysis genes) for
both tumour and healthy samples, for these genomic regions
located closer to the promoter across all tissue types, however the
most unstable meta-analysis genes are also associated with a large
variability of methylation levels (Figure S4). The least unstable
meta-analysis genes conversely are associated with consistently
very low levels of methylation in both tumour and healthy samples
for these genomic regions, and particularly for TSS200, 59UTR
and 1stExon, suggesting that the low methylation instability of
these genes is associated with a lack of methylation in the most
functionally important genomic regions in both diseased and
normal tissues, and therefore that regulation of these genes is by
mechanisms other than those involving DNA methylation, in
particular the availability of transcription factors.
Correlation of Tumour Gene Expression with Intra-gene
Methylation Architecture
In order to investigate the effect of intra-gene methylation
architecture on gene expression, the 217 BRCA tumour samples
with matched gene expression and methylation data available
from TCGA were considered in more detail. For each gene a non-
linear multivariate regression analysis was performed (see ‘Meth-
ods and Models’) of gene expression to intra-gene methylation
architecture, for these matched tumour samples, taking gene
expression as the response, and taking one of mean z-score, mean
derivative and methylation variance as one covariate predictor,
together with mean methylation as a second covariate predictor.
The relative proportions of genes found as significant or not, and
significant according to one covariate or the other, or both, are
shown in Figure 4; in particular there are many genes with
expression not significantly predicted by mean methylation but
significantly predicted by mean z-score, mean derivative, or
methylation variance.
Enrichment by stem cell genes of genes with expression
significantly predicted by only one covariate was again tested to
confirm the biological significance of findings with reference to
genes which are well known to be important in cancer biology. It
was found that genes with expression predicted by only the mean
z-score covariate were significantly enriched by Biv ES genes and
PCGTs (p~1:3|10{3 and p~5:0|10{3 respectively, Fisher’s
exact test), a result which is consistent with the findings here that
Biv ES genes are enriched among the most unstable meta-analysis
genes, i.e., those genes which are most consistently associated with
the biggest difference in methylation pattern between cancer and
healthy phenotypes. It was also found that, correspondingly, genes
with expression predicted by only the mean methylation covariate
in the multivariate regression with the mean z-score covariate were
significantly enriched (p~9:0|10{4, Fisher’s exact test) by H3K4
ES genes, a result which is consistent with our findings that H3K4
ES genes are enriched among least unstable meta-analysis genes,
i.e., those genes which have consistently least difference in
methylation pattern between cancer and healthy phenotypes.
Similarly, it was found that genes with expression predicted by
only the mean derivative covariate were significantly enriched by
Biv ES genes and PCGTs (p~9:5|10{4 and p~8:4|10{4
respectively, Fisher’s exact test) and that genes with expression
predicted only by the mean methylation covariate in the same
Table 2. Enrichment of MUs and LUs genes by stem cell
genes.
H3K27 H3K4 Biv PCGT
MUs 1.43610–28 1 5.19610–278 1.77610–234
LUs 1 4.33610–70 1 1
P-values (one-sided Fisher’s exact test) show enrichment of most unstable
meta-analysis genes (MUs) and enrichment of least unstable meta-analysis
genes (LUs) by genes in various SC categories. This confirms the biological
significance of the findings of the meta-analysis with reference to these genes
which are well known to be important in cancer biology.
doi:10.1371/journal.pone.0068285.t002
Figure 4. Correlation of expression to intra-gene methylation
architecture, for matched BRCA samples. Expression was taken as
the response variable, with one of mean z-score, mean derivative and
methylation variance as one covariate predictor, together with mean
methylation as a second covariate predictor. (a) The proportion of
genes with at least one covariate significant (FDR qƒ0:05), and the
proportion of genes with neither covariate significant. (b) The
proportion of significant genes (i.e., the proportion of the genes
represented by the left of each pair of bars in a) which are significant
due to one, or the other, or both covariates. For the genes which are
significant due to only one covariate predictor, the proportions of these
genes for which the significance is due to positive or negative
correlation are indicated on the bars with/and \ respectively. There are
many genes with expression not significantly predicted by mean
methylation but significantly predicted by mean z-score, mean
derivative, or methylation variance.
doi:10.1371/journal.pone.0068285.g004
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multivariate regression were significantly enriched by H3K4 ES
genes (p~3:1|10{4, Fisher’s exact test).
These findings extend to heterogeneous tumour phenotype, as
defined by gene expression, the idea that differences in methyl-
ation patterns in stem cell genes are a hallmark of cancer, and
shows that this can be measured by intra-gene methylation
architecture in the form of intra-gene methylation variability
(according to the mean derivative and methylation variance
measures) and instability (according to the mean z-score measure)
more accurately than by mean methylation level alone.
Association of Genome-wide Mean z-score with Breast
Cancer Intrinsic Subtypes
Differences in intra-gene methylation architecture between
heterogenous tumour phenotypes (as defined by gene expression)
was further explored, in the context of breast cancer intrinsic
subtypes. The same 217 BRCA samples with matched gene
expression and methylation data available were each uniquely
assigned to one of these disease subtypes, according to established
molecular definitions, using the PAM50 classifier [20]. This was
done by correlating the gene expression profile (Spearman
correlation) for each sample to the PAM50 classifier canonical
gene expression profiles for 5 different intrinsic subtypes, and for
each sample choosing the subtype with the largest correlation
coefficient, leading to 42 samples classified as Basal, 24 as Her2, 81
Luminal A, 54 Luminal B, and 16 classified as Normal. For each
of these samples, a genome-wide mean z-score was also calculated,
as a per-sample genome-wide measure of intra-gene methylation
architecture. The distributions of these genome-wide mean z-
scores for each intrinsic subtype are shown in Figure 5; there are
clear differences in the means and distributions between each of
the subtypes. A Kruskal-Wallis test was carried out to check the
significance of these differences, with a very significant result,
p~1:4|10{12. Removing the samples classified as Luminal B
and Normal (as the distributions of genome-wide mean-z scores
have larger and smaller variances, respectively, for these subtypes
than the others), still resulted in a significant result in the Kruskal-
Wallis test, p~0:023. This ability to distinguish between
heterogenous tumour phenotypes, in the context of established
molecular definitions of disease subtypes, indicates that it may be
possible to use intra-gene methylation architecture to develop new
molecular classifiers of cancer, or make established ones more
robust. This is particularly interesting, since methylation levels are
typically more stable than gene expression levels.
Discussion
We have shown that the reorganisation of intra-gene methyl-
ation architecture is a fundamental characteristic of cancer cells,
and that there are many ways to assess these differences, which can
provide complimentary information. We have developed measures
to detect some of these differences, including the first investigation
of intra-gene variability of methylation (as opposed to sample to
sample variability of methylation). We have shown that our mean
z-score measure is consistently more effective at predicting cancer
compared to healthy phenotype than mean methylation, even
after adjustment for the mean methylation level.
We have carried out what is, to our knowledge, the largest meta-
analysis performed in any DNA methylation study. In particular,
over 4000 genes were found to be significantly associated with a
consistent difference between cancer and healthy phenotypes,
demonstrating that, as a method for distinguishing cancer from
healthy tissue, our mean z-score measure is robust to differences
between tumour types. The 100 most significant genes according
to this meta-analysis (Table S1) can be considered as particularly
characteristic of a generalised and non tissue-specific cancer
phenotype. These least unstable meta-analysis genes are also
significantly enriched (Table 2) by genes carrying H3K27 and
bivalent chromatin marks in ES cells and by PCGTs, consistent
with the idea that the tumour phenotype is associated with the
acquisition of stem-like cell characteristics [15]. In this meta-
analysis, over 2800 genes were also found to be significantly
associated with an absence of difference in methylation pattern
from healthy to cancer, and these are significantly enriched by
genes carrying the activating H3K4 chromatin mark in ES cells
(Table 2).
There is a particularly big contrast in the effectiveness of these
methods with respect to endocrine cancers. On the one hand,
these methods are particularly insensitive to PRAD and THCA
(Figure 2), and furthermore, the genes identified as being most
significant in the meta-analysis do not seem to show the same
pattern of instability in these cancers (Figure 3). This suggests the
possibility that epigenetic mechanisms may, in general, be less
relevant to oncogenic processes in THCA and PRAD. On the
other hand, These methods are very effective at determining
differences in epigenetic patterns with respect to both BRCA and
UCEC (Figure 2), and these cancers show significant patterns of
instability in a large proportion of the genes identified as being
most significant in the meta-analysis (Figure 3).
The correlation for tumour samples of gene expression to intra-
gene methylation architecture (Figure 4) shows that there are a
substantial number of genes for which mean methylation is not
significantly predictive of gene expression but other measures of
intra-gene methylation architecture are. In particular, in the case
of our mean z-score and mean derivative measures, genes with
Figure 5. Distributions of genome-wide mean z-score, for
breast cancer intrinsic subtypes. The mean across all genes of the
mean z-scores was calculated for the 217 BRCA samples with matched
expression and methylation data available. These samples were
independently classified by correlation of their gene expression profiles
(Spearman correlation) with those of the PAM50 breast cancer intrinsic
subtype classifier [20]. The distributions of these genome-wide mean z-
scores, for each intrinsic subtype, are shown in the boxplots. Indicated
significance was calculated using the Kruskal-Wallis test.
doi:10.1371/journal.pone.0068285.g005
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expression predicted by these measures and not by mean
methylation are enriched by Biv ES genes and PCGTs, suggesting
that the intra-gene methylation instability and variability are able
to provide important information about heterogeneous tumour
phenotype (as measured by gene expression), particularly in
relation to stem-like cell characteristics, which is beyond the reach
of measures based on mean methylation level alone.
The differences in the genome-wide mean z-scores across breast
cancer intrinsic subtypes (Figure 5) highlight the potential of intra-
gene methylation architecture to distinguish between heterogenous
tumour phenotypes in the context of established gene expression
based definitions of distinct subtypes of this disease. This indicates
that it may be possible to use intra-gene methylation architecture
to develop new molecular classifiers of cancer, or make established
ones more robust.
Further improvements in classification by our methods will be
gained by the inclusion of complementary epigenetic data, in
particular those which measure patterns of histone modification.
As discussed, it is well established how crucial genes which carry
important histone markings in stem cells are to understanding
cancer biology. By extending the view of the epigenetic landscape
beyond DNA methylation to consider also histone markings not
just in stem cells but also in mature healthy cells and cancer cells,
we will gain mechanistic insights into the interaction between
intra-gene methylation architecture and histone modifications.
In summary, we have shown for the first time that generalised
differences in intra-gene methylation architecture are a better
predictor of phenotype than mean methylation level alone, and we
have developed novel measures of these differences, which offer a
considerable reduction in complexity from per CpG methylation
measures (hundreds of thousands of features) to per gene
methylation measures (tens of thousands of features). We have
shown that there are many genes with expression predicted by
measures of intra-gene methylation architecture other than mean
methylation level, and therefore that more general measures of
intra-gene methylation architecture offer novel information about
heterogeneous tumour phenotype (as defined by gene expression).
We have also shown that intra-gene methylation architecture is
able to distinguish between established molecular definitions of
heterogenous cancer subtypes. Because it has been shown
previously that differences in methylation pattern occur prior to
the onset of disease [18], we anticipate that our measures of intra-
gene methylation architecture might also be able to efficiently find
pre-disease methylation patterns. We therefore believe that our
measures of intra-gene methylation architecture have potential for
further development as DNA based cancer biomarkers.
Methods and Models
Data Source and Preprocessing
Methylation data, collected via the Illumina Infinium Human-
Methylation450 platform, were downloaded from The Cancer
Genome Atlas (TCGA) project [19] at level 3. These data were
obtained from fourteen different tumour types, as follows: Bladder
Urothelial Carcinoma (BLCA), Breast Invasive Carcinoma
(BRCA), Colon Adenocarcinoma (COAD), Head and Neck
Squamous Cell Carcinoma (HNSC), Kidney Renal Clear Cell
Carcinoma (KIRC), Kidney Renal Papillary Cell Carcinoma
(KIRP), Liver (LIHC), Lung Adenocarcinoma (LUAD), Lung
Squamous Cell Carcinoma (LUSC), Pancreatic Adenocarcinoma
(PAAD), Prostate Adenocarcinoma (PRAD), Rectum Adenocarci-
noma (READ), Thyroid Carcinoma (THCA), and Uterine Corpus
Endometrioid Carcinoma (UCEC).
These data were pre-processed by first removing probes with
non-unique mappings and which map to SNPs (as identified in the
TCGA level 3 data); probes mapping to sex chromosomes were
also removed; in total 98384 probes were removed in this way
from all data sets. After removal of these probes, 270985 probes
with known gene annotations remained. Individually for each data
set, probes were then removed if they had less than 95% coverage
across samples; probe values were also replaced if they had
corresponding detection p-value greater than 5%, by KNN (k
nearest neighbour) imputation (k~5).
Matched gene expression data were also downloaded for 217
samples for the BRCA data set, and were quantile normalised.
Intra-gene Methylation Measures
Four methylation measures were considered, and were calcu-
lated separately for each sample, for each gene:
N ‘Mean z-score’: the mean of the z-scores calculated from the
methylation values for the probes mapping to the gene, with
population parameters for each probe calculated from healthy
control samples
N ‘Mean derivative’: the mean absolute derivative of the
methylation profile across the gene
N ‘Methylation variance’: the variance of the methylation values
for probes mapping to one genomic region of the gene
N ‘Mean methylation’: the mean of the methylation values for
probes mapping to one genomic region of the gene
To calculate the mean of the z-scores for each gene, the R [21]/
Bioconductor [22] package ‘IlluminaHumanMethylation450k’
[23] was used to identify the probes mapping to each gene. Then
for each probe, the mean and standard deviation of the
methylation values for that probe were found from healthy tissue
samples, allowing a z-score zi,j for each probe i, and for each
sample j, to be calculated according to equation 1. By taking the
mean of the absolute zi,j for all probes i mapping to gene g, a
single intra-gene methylation predictor value xj(g) was then
calculated for each gene g, for each sample j, according to
equation 2. A regularisation parameter, j, was added to each
probe standard deviation when calculating probe z-scores to
prevent very large values from occurring; j was chosen to be 0.01
after considering the distribution of probe standard deviations
(Figure S5).
zi,j~
Dbi,j{m
(h)
i D
s(h)i zj
~
di,j
s(h)i zj
ð1Þ
xj(g)~
1
n(g)
X
i[P(g)
zi,j ð2Þ
where bi,j is the methylation value for probe i and sample j, m
(h)
i
and s
(h)
i are the mean and standard deviation of the methylation
values corresponding to the relevant healthy tissue samples for
probe i, n(g) denotes the number of probes mapping to gene g and
P(g) is the set of probes mapping to gene g.
To calculate the ‘mean derivative’ methylation measure, the
‘IlluminaHumanMethylation450k’ package was again used to find
the probes mapping to each gene. Ordering the probes
P(g)~fi(1),:::,i n(g)ð Þg mapping to gene g as they are positioned
along the DNA, the derivative of the methylation profile for gene g
and sample j is estimated as the differences between the beta
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values at consecutive probes; hence the mean derivative for this
gene and sample is estimated according to equation 3.
xj gð Þ~ 1
n(g){1
X
1ƒkvn(g)
Dbi(kz1),j{bi(k),j D ð3Þ
In this way, a single intra-gene methylation predictor value
xj(g) was calculated for each gene g, for each sample j.
To calculate the ‘methylation variance’ and ‘mean methylation’
measures, first the most effective genomic region, for each of these
measures, across which to calculate these measures for each gene,
was selected. For this, annotation information for the probes used
by the Illumina Infinium platform was obtained from Gene
Expression Omnibus (GEO) [24]. This annotation information
details which probes map to one of six genomic regions for each
gene, as follows: (1) TSS1500; probes annotated to distances
greater than 200 bp and less than 1500 bp upstream from the TSS
(transcriptional start site) of the gene. (2) TSS200; probes
annotated to within 200 bp upstream of the TSS of the gene. (3)
59UTR; probes annotated to the 5-prime untranslated region of
the gene. (4) 1stExon; probes annotated to the first exon of the
gene. (5) Body; other probes annotated to the gene body. (6)
39UTR; probes annotated to the 3-prime untranslated region of
the gene.
Separately for each of these genomic regions, the variance of
methylation levels for each gene for probes mapping to the
genomic region in question was calculated. Then the effectiveness
of each genomic region at discriminating between healthy and
tumour tissue was compared, by considering the correlation of the
tissue sample phenotype to the methylation variance measure in
terms of distributions of per-gene AUCs; the ‘Body’ (gene body)
genomic region was chosen for the methylation variance measure,
as it performed best in 13 out of 14 data sets (Figure S1). This
methylation variance was calculated for each gene for which there
was ‘Body’ annotation information available, to give a single intra-
gene methylation predictor value xj(g), for each gene g, for each
sample j.
It should be noted, however, that in general for each gene there
were far more probes annotated as ‘Body’ than for other genomic
regions (Table 3), leading to better estimates of the methylation
variance for this region. Therefore, the relative greater effective-
ness of this genomic region in this comparison does not necessarily
imply biological significance. The minimum number of probes to
be able to calculate the methylation variance for a given gene and
genomic region was set to be 3, and the methylation variance was
not calculated for any gene with any fewer annotated probes than
this for a given genomic region. As there were more genes with at
least 3 probes annotated to the ‘Body’ region (Table 3), it would be
expected that there would be more genes which significantly
associate with phenotype when this genomic region is used, which
is likely to be another reason it performs better, without relevance
to biological significance.
To choose which region to use to calculate the mean
methylation measure, the same procedure was followed as for
the methylation variance measure; the ‘Body’ genomic region was
similarly chosen as this region correlated best with cancer/healthy
phenotype in 10 out of 14 data sets (Figure S2). This mean
methylation measure was calculated for each gene for which there
was ‘Body’ annotation information available, to give a single intra-
gene methylation predictor value xj(g), for each gene g, for each
sample j. It is again worth noting that it is likely to be be due to the
greater number of probes per gene annotated to ‘Body’, and the
corresponding increase in accuracy of the calculated estimates of
the mean methylation, which leads to this genomic region being
more effective in this comparison, rather than there being any
biological significance to this finding. In the case of mean
methylation, it was only required that there be one probe
annotated to a genomic region to allow a mean methylation level
to be represented for that genomic region for that gene, as
methylation levels of neighbouring CpGs within the same genomic
region are expected to be highly correlated; again, there were
more genes with at least one probe annotated to the ‘Body’ region
than the other regions (Table 3), similarly suggesting a reason for
its better performance other than biological significance.
Comparison of Intra-gene Methylation Measures
Methylation measures were assessed according to the distribu-
tions of their per-gene AUCs. The AUC is the ROC (receiver-
operator characteristic) ‘area under curve’ and is defined as the
probability that a randomly chosen item from the ‘positive’ class
will be scored higher than a randomly chosen item from the
‘negative’ class [25].
The same procedure was used for the main comparison of intra-
gene methylation measures, for the choice of genomic region used
in the methylation variance measure, and for the choice of
genomic region used in the mean methylation measure. In this
procedure, each data set was split half and half into a training and
test set, maintaining the same proportion of cancer and healthy
samples in both sets. Using only the training set, AUCs were
calculated for all genes, and the top 1000 genes were selected as
those with the best AUC. Then using the test set, an AUC was
calculated for each of these top 1000 genes identified in the
training set. For the mean z-score measure, the mean healthy
methylation profiles and healthy methylation standard deviations
calculated from the training set were used to calculate the z-scores
for both the cancer and healthy samples in the test set. The
distributions of these test-set AUCs were compared in distribution
density plots and using the Kolmogorov-Smirnov test (Figure 2
and Figures S1 and S2).
Meta-analysis and Gene-set Enrichment Analysis
A meta-analysis of the fourteen data sets was carried out. The
mean across all data sets of the per-gene AUCs generated from
Table 3. Number of probes per genomic region and gene, of
18272 annotated genes.
TSS1500 TSS200 59UTR 1stExon Body 39UTR
Mean no.
probes
2.7 2.4 2.5 1.5 7 0.82
Median no.
probes
2 2 1 1 3 1
No. probes,
95% CI
(0–10) (0–7) (0–13) (0–6) (0–39) (0–4)
No. genes
with min
3 probes
8512 7570 5258 3734 10029 958
No. genes
with min
1 probe
14259 12979 11408 12194 15858 10291
No. genes
with 0
probes
4013 5293 6864 6078 2414 7981
doi:10.1371/journal.pone.0068285.t003
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the mean z-score measure was calculated for each gene.
Significance was then assigned to each of these per-gene mean
AUCs by similarly calculating null mean AUCs after permuting
AUCs within data sets. This resulted in 4267 significant
unstable meta-analysis genes with FDR q-value [26] less than
5%, i.e., those genes corresponding to the upper tail of the null
mean AUC distribution, which are associated with a consistent
difference between cancer and healthy phenotypes across tissue
types; the top 100 most significant of these unstable genes
appear in Table S1. This permutation method also resulted in
2818 significant (FDR qƒ0:05) significant least unstable meta-
analysis genes, i.e., those genes corresponding to the lower tail
of the null mean AUC distribution, which were associated with
least difference from healthy to cancer phenotype across tissue
types the top 100 most significant of these least unstable genes
appear in Table S2.
To confirm the biological significance of the findings of this
meta-analysis with reference to genes which are well known to
be important in cancer biology, the least unstable and least
unstable meta-analysis genes were tested for enrichment by
genes which in ES cells carry the repressing/activating
chromatin marks H3K27me3 (H3K27 ES genes), H3K4me3
(H3K4 ES genes) and bivalent (i.e., both H3K27me3 and
H3K4me3 marks, Biv ES genes) and enrichment by PCGTs
(ES cell polycomb group target genes) using the one-tailed
Fisher’s exact test. A more general gene-set enrichment analysis
(GSEA) was also carried out both on the least unstable and least
unstable meta-analysis genes; 6811 gene set definitions were
downloaded from the Broad Institute Molecular Signatures
Database (http://www.broadinstitute.org/), and each gene set
was tested separately for enrichment among the significant
genes. Enrichment was again tested using the one-sided Fisher’s
exact test, finding 1048 and 778 gene sets significantly (FDR
qƒ0:05) enriched by least unstable and least unstable meta-
analysis genes respectively. The top 100 of these gene sets are
shown in tables S3 and S4 respectively.
Correlation of Tumour Gene Expression with Intra-gene
Methylation Architecture
For the 217 BRCA tumour samples for which matched gene
expression and methylation data were available, for each gene a
multivariate regression analysis of gene expression and intra-gene
methylation architecture was carried out. Gene expression was
used as the response, with one of mean z-score, mean derivative
and methylation variance as one covariate predictor, and with
mean methylation as a second covariate predictor. As it was
expected that this relationship would be non-linear, and as for a
non-specified non-linear monotonic function the ranks of data
points in response and predictor variables are linearly related if
there is a good association between these variables, the ranks of
each of the variables across the samples were correlated to one
another, as follows.
Defining for gene g the ranks of the samples according to the
expression data as r(e)(g), the ranks of the samples according to the
mean z-score, mean derivative or methylation variance as r(x)(g),
and the ranks of the samples according to the mean methylation as
r(m)(g), the data were modelled according to equation 4:
r(e)(g)~a(g)r(x)(g)zc(g)r(m)(g)zm(g)z[ ð4Þ
where m(g) is the intercept term for gene g, and is the model error.
Where r(e)(g) is well-correlated with r(x)(g), similar integer entries
in these vectors (corresponding to similar ranks) will appear in
similar positions in these vectors (N.B., these vectors are not
themselves ordered). This will then be reflected as a small p-value
for this comparison (calculated from the corresponding t-statistic
for the linear model a(g) coefficient), and similarly for r(m)(g) (and
corresponding c(g) coefficient), if it is well-correlated with r(e)(g).
This linear model was applied to the data for each gene present
in the matched expression and methylation data for the BRCA
dataset. ‘Body’ annotated probes were again used to calculate the
methylation variance and mean methylation measures as used in
this model, because probes annotated to this genomic region
produced, in both cases, the greatest number of significant p-
values (for the respective covariate), as compared to using probes
annotated to each of the other genomic regions.
Supporting Information
Figure S1 Distributions of per-gene AUCs calculated
from genomic feature methylation variance measures.
P-values shown are for Kolmogorov-Smirnov tests comparing the
distributions of the most effective and second most effective
measures.
(PDF)
Figure S2 Distributions of per-gene AUCs calculated
from genomic feature mean methylation measures. P-
values shown are for Kolmogorov-Smirnov tests comparing the
distributions of the most effective and second most effective
measures.
(PDF)
Figure S3 Scatter plots showing pairwise comparisons
of each of the four methylation measures, for the
ONECUT3 gene. ONECUT3 was among the top 1000 genes
with the highest AUC according to each of the four methylation
measures. There is one point in each scatter plot for each of the 98
healthy and 586 cancer samples in the BRCA data set.
(PDF)
Figure S4 Genomic feature mean methylation levels for
healthy and tumour samples. (1) significant consistently most
unstable genes in the meta-analysis (sig MUs) (2) genes not
significant in the meta-analysis, (3) significant consistently least
unstable genes in the meta-analysis (sig LUs).
(PDF)
Figure S5 Distributions of probe standard deviations.
For each tumour type, the standard deviation of the beta values for
each probe is found for cancer and for healthy samples; then
estimates of the density distributions of the standard deviations for
all probes are plotted for cancer and healthy samples for each
tumour type. Locations of the modal standard deviation of each
density distribution estimate are indicated with dashed lines, and
are stated on each plot; where the distribution is multimodal the
modal standard deviation corresponding to the greatest density is
used.
(PDF)
Table S1 Meta-analysis: 100 most significant most
unstable genes.
(PDF)
Table S2 Meta-analysis: 100 most significant least
unstable genes.
(PDF)
Table S3 Meta-analysis GSEA: most unstable genes, 100
most significant gene-sets.
(PDF)
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Table S4 Meta-analysis GSEA: least unstable genes, 100
most significant gene-sets.
(PDF)
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